Cargando…
Compassionate use of experimental therapies: who should decide?
In addition to being an example of unsubstantiated hype about regenerative medicine, the controversy around the Italy-based Stamina Foundation's unproven stem cell therapy represents another chapter in a continuing debate about how to balance patients' requests for early access to experime...
Autor principal: | Zettler, Patricia J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604679/ https://www.ncbi.nlm.nih.gov/pubmed/26202382 http://dx.doi.org/10.15252/emmm.201505262 |
Ejemplares similares
-
Who should decide how much and what information is important in person-centred health care?
por: Kaltoft, Mette Kjer, et al.
Publicado: (2015) -
Towards Better Pharmaceutical Provision in Europe—Who Decides the Future?
por: Horgan, Denis, et al.
Publicado: (2022) -
COVID: Its compassionate use
por: Bennett, Jasmiry
Publicado: (2020) -
Reimagining the future of natural history museums with compassionate collection
por: Byrne, Allison Q.
Publicado: (2023) -
Decision‐making at the borderline of viability: Who should decide and on what basis?
por: Gillam, Lynn, et al.
Publicado: (2017)